Korean Journal of Biological Psychiatry (생물정신의학)

The Korean Society of Biological Psychiatry (대한생물정신의학회)
권호 표지

A Case of Clozapine-Induced Myocarditis

Clozapine에 의한 심근염 1예

  • Jo, Woo-Dong (Department of Psychiatry & Behavioral Sciences, Ajou University School of Medicine) ;
  • Choi, Byoung-Joo (Department of Cardiology, Ajou University School of Medicine) ;
  • Noh, Jai-Sung (Department of Psychiatry & Behavioral Sciences, Ajou University School of Medicine)
  • 조우동 (아주대학교 의과대학 정신건강의학교실) ;
  • 최병주 (아주대학교 의과대학 순환기내과학교실) ;
  • 노재성 (아주대학교 의과대학 정신건강의학교실)
  • Received : 2012.04.12
  • Accepted : 2012.05.11
  • Published : 2012.08.31
Download PDF
⟨ Previous Next ⟩

Abstract

Clozapine is an atypical antipsychotic agent that is more effective than the typical neuroleptics in the treatment of refractory schizophrenia. Recently, there has been an increased recognition of the association of clozapine with myocarditis and cardiomyopathy. Commonly used diagnostic tests have limited sensitivity in diagnosing this potentially life-threatening complication. Here we report a case of 36-year-old male patient who developed fever, tachycardia, and dyspnea after introduction of clozapine. By clinical evaluation and laboratory test we diagnosed the patient with myocarditis and treated him successfully. To our knowledge this is the first case report of clozapine-induced myocarditis in Korea.

Keywords

References

  1. Owens DG. Adverse effects of antipsychotic agents. Do newer agents offer advantages? Drugs 1996;51:895-930. https://doi.org/10.2165/00003495-199651060-00001
  2. Conley RR. Optimizing treatment with clozapine. J Clin Psychiatry 1998;59 Suppl 3:44-48.
  3. McElroy SL, Dessain EC, Pope HG Jr, Cole JO, Keck PE Jr, Frankenberg FR, et al. Clozapine in the treatment of psychotic mood disorders, schizoaffective disorder, and schizophrenia. J Clin Psychiatry 1991;52:411-414.
  4. Suppes T, McElroy SL, Gilbert J, Dessain EC, Cole JO. Clozapine in the treatment of dysphoric mania. Biol Psychiatry 1992;32:270-280. https://doi.org/10.1016/0006-3223(92)90108-C
  5. Meltzer HY, Okayli G. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am J Psychiatry 1995;152:183-190. https://doi.org/10.1176/ajp.152.2.183
  6. Volavka J, Zito JM, Vitrai J, Czobar P. Clozapine effects on hostility and aggression in schizophrenia. J Clin Psychopharmacol 1993;13: 287-289.
  7. Krakowski MI, Czobor P, Citrome L, Bark N, Cooper TB. Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2006;63:622-629. https://doi.org/10.1001/archpsyc.63.6.622
  8. Weintraub D, Hurtig HI. Presentation and management of psychosis in Parkinson's disease and dementia with Lewy bodies. Am J Psychiatry 2007;164:1491-1498. https://doi.org/10.1176/appi.ajp.2007.07040715
  9. Baldessarini RJ, Frankenburg FR. Clozapine. A novel antipsychotic agent. N Engl J Med 1991;324:746-754. https://doi.org/10.1056/NEJM199103143241107
  10. Alvir JM, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med 1993;329:162-167. https://doi.org/10.1056/NEJM199307153290303
  11. Roh S, Ahn DH, Kim YS, Lee BH. Dilated cardiomyopathy associated with clozapine. J Korean Neuropsychiatr Assoc 2005;44:125-128.
  12. Young CR, Bowers MB Jr, Mazure CM. Management of the adverse effects of clozapine. Schizophr Bull 1998;24:381-390. https://doi.org/10.1093/oxfordjournals.schbul.a033333
  13. Mackin P. Cardiac side effects of psychiatric drugs. Hum Psychopharmacol 2008;23 Suppl 1:3-14. https://doi.org/10.1002/hup.915
  14. Hagg S, Spigset O, Bate A, Soderstrom TG. Myocarditis related to clozapine treatment. J Clin Psychopharmacol 2001;21:382-388. https://doi.org/10.1097/00004714-200108000-00005
  15. Kilian JG, Kerr K, Lawrence C, Celermajer DS. Myocarditis and cardiomyopathy associated with clozapine. Lancet 1999;354:1841-1845. https://doi.org/10.1016/S0140-6736(99)10385-4
  16. La Grenade L, Graham D, Trontell A. Myocarditis and cardiomyopathy associated with clozapine use in the United States. N Engl J Med 2001;345:224-225. https://doi.org/10.1056/NEJM200107193450317
  17. Commitee on safety of medicines. Myocarditis with antipsychotics: recent cases with clozapine (clozaril). Current Problems in Pharmacovigiliance 1993;19:9-10.
  18. Coulter DM, Bate A, Meyboom RH, Lindquist M, Edwards IR. Antipsychotic drugs and heart muscle disorder in international pharmacovigilance: data mining study. BMJ 2001;322:1207-1209. https://doi.org/10.1136/bmj.322.7296.1207
  19. Novartis. Dear health care provider: myocarditis added to boxed warning;2002.
  20. Haas SJ, Hill R, Krum H, Liew D, Tonkin A, Demos L, et al. Clozapine-associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993-2003. Drug Saf 2007;30:47-57. https://doi.org/10.2165/00002018-200730010-00005
  21. Calabrese F, Thiene G. Myocarditis and inflammatory cardiomyopathy: microbiological and molecular biological aspects. Cardiovasc Res 2003;60:11-25. https://doi.org/10.1016/S0008-6363(03)00475-9
  22. Ruetsch O, Viala A, Bardou H, Martin P, Vacheron MN. [Psychotropic drugs induced weight gain: a review of the literature concerning epidemiological data, mechanisms and management]. Encephale 2005;31(4 Pt 1):507-516. https://doi.org/10.1016/S0013-7006(05)82412-1
  23. Razminia M, Salem Y, Devaki S, Shah N, Khosla S. Clozapine induced myopericarditis: early recognition improves clinical outcome. Am J Ther 2006;13:274-276. https://doi.org/10.1097/01.mjt.0000212704.79248.3d
  24. Feldman AM, McNamara D. Myocarditis. N Engl J Med 2000;343:1388-1398. https://doi.org/10.1056/NEJM200011093431908
  25. Tham JC, Dickson RA. Clozapine-induced fevers and 1-year clozapine discontinuation rate. J Clin Psychiatry 2002;63:880-884. https://doi.org/10.4088/JCP.v63n1005
  26. Kim Y, Ahn Y, Jeong S, Shin Y. Clinical use of clozapine: 89 questions and answers. Seoul: Seoul National University Press;2009. p.167-169.
  27. Pollmacher T, Schuld A, Kraus T, Haack M, Hinze-Selch D. [On the clinical relevance of clozapine-triggered release of cytokines and soluble cytokine-receptors]. Fortschr Neurol Psychiatr 2001;69 Suppl 2:S65-S74. https://doi.org/10.1055/s-2001-16533
  28. Burian J, Buser P, Eriksson U. Myocarditis: the immunologist's view on pathogenesis and treatment. Swiss Med Wkly 2005;135:359-364.
  29. Vaddadi KS, Soosai E, Vaddadi G. Low blood selenium concentrations in schizophrenic patients on clozapine. Br J Clin Pharmacol 2003;55:307-309. https://doi.org/10.1046/j.1365-2125.2003.01773.x
  30. Hill GR, Harrison-Woolrych M. Clozapine and myocarditis: a case series from the New Zealand Intensive Medicines Monitoring Programme. N Z Med J 2008;121:68-75.
  31. Dukes MN. The importance of adverse reactions in drug regulation. Drug Saf 1990;5:3-6. https://doi.org/10.2165/00002018-199005010-00002
  32. Wooltorton E. Antipsychotic clozapine (Clozaril): myocarditis and cardiovascular toxicity. CMAJ 2002;166:1185-1186.
  33. Degner D, Bleich S, Grohmann R, Bandelow B, Ruther E. Myocarditis associated with clozapine treatment. Aust N Z J Psychiatry 2000;34:880. https://doi.org/10.1080/j.1440-1614.2000.0822n.x